Biotechnology SMEs, start-ups, spin-offs or microenterprises are they molecules coming from the research results? If so, what place do they hold in the global industrial tissue?
In recent years, the number of biotech enterprises in Europe has grown spectacularly, largely fueled by the increasing number of entrepreneurial initiatives from Europe's leading research institutes. The place held on the economic market by these enterprises, is a question that market analysts have been asking themselves since their rapid growth and, more particularly, their over valuation which, at times, has led to the crash of their shares on the stock markets. To be sure, this article does not claim to go into an in-depth financial analysis to explain the details of certain "shipwrecks". Rather, it just would like to provide some useful indications for all those having embarked, or desirous of doing so, in the creation of biomedical enterprises.